Terence Flotte is a prominent inventor based in Baltimore, MD (US), known for his significant contributions to the field of gene therapy. He holds a total of five patents, showcasing his innovative approach to medical science and biotechnology.

Latest Patents

One of his latest patents involves a modified adeno-associated virus vector capable of expression from a novel transcription promoter. This invention describes constructions of recombinant DNA comprising modified adeno-associated virus (AAV) DNA sequences that function as a eukaryotic expression vector. The vector has been shown to successfully express a test reporter gene in mammalian cells. Furthermore, it can introduce and express a human gene, correcting genetic defects caused by malfunctioning endogenous genes. This technology also allows for the expression of a modified version of the human gene, which consists of a fusion of part of the gene and a synthetic sequence contained in the vector.

Career Highlights

Terence Flotte has made remarkable strides in the field of gene therapy, particularly through his work with the United States of America as represented by the Department of Health. His research has paved the way for advancements in treating genetic disorders, demonstrating the potential of gene therapy in modern medicine.

Collaborations

Throughout his career, Terence has collaborated with notable colleagues, including Barrie J Carter and Sandra Afione. These partnerships have contributed to the success of his research and the development of innovative solutions in gene therapy.

Conclusion

Terence Flotte's work exemplifies the intersection of innovation and healthcare, making significant strides in the field of gene therapy. His contributions continue to influence the future of medical science and the treatment of genetic disorders.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com